Key Record Dates Identifier: NCT04109066
Brief Title: Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)

First Submitted : September 27, 2019
First Submitted that Met QC Criteria : September 27, 2019
First Posted : September 30, 2019

Last Update Submitted that Met QC Criteria : October 15, 2021
Last Update Posted : October 18, 2021